AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06364306 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotically-assisted ventral hernia repair (RVHR)
Description: 3 8mm robotic trocars are placed intraabdominally and the DaVinci Xi-robotic system is docked. Adhesiolysis from any adherent structures to the abdominal wall is performed. Incision of the lateral verge of the retromuscular space and retromuscular dissection. Superior and inferior cross-over to the contralateral retromuscular space and dissection of the hernia sac.~Unilateral or bilateral transversus abdominis release (TAR) is performed, if necessary. Running suture with absorbable barbed suture of the posterior rectus sheath and peritoneum, as appropriate. Synthetic retromuscular mesh placement with a mesh-size as large as the prepared surface allows. Closure of the anterior rectus sheath with absorbable barbed running suture. Port extraction, skin closure. Dressing from xyphoid to pubis and 6 lateral dressings for blinding purposes.
Study NCT06497933 — intervention group
Intervention type: PROCEDURE
Intervention: Atrial fibrillation ablation
Description: Pulmonary veins isolation potentially associated with other atrial lesions, performed with the pentaspline PFA catheter
Study NCT06364306 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open ventral hernia repair (OVHR)
Description: Median laparotomy with a minimal length of the previous scar (in case of incisional hernia) and adhesiolysis is performed, where necessary, to liberate the abdominal wall and the ventral hernia from adhesions. Bilateral dissection of the posterior rectus sheath under visualisation and sparing of the epigastric vessels and neurovascular bundles. Closure of the posterior rectus sheath with a slowly-absorbable running suture. Indication for a uni- or bilateral TAR identical to the intervention group. Retromuscular synthetic mesh placement with a mesh-size as far as the prepared surface allows. Mesh fixation optional with either absorbable sutures to the posterior sheath or with glubran glue. Closure of the anterior rectus sheath with a slowly-absorbable running suture. Skin closure. Dressing from xyphoid to pubis and 6 lateral dressings for blinding purposes.
Study NCT04974944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: IV injection
Study NCT04974944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Oral
Study NCT04974944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV injection
Study NCT04974944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: IV infusion
Study NCT04974944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion
Study NCT04974944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: IV infusion
Study NCT06304194 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Analysis of biological samples
Description: The collected biological sample will be isolated and the specific nucleic acid (DNA/RNA/cfDNA) extracted for molecular analysis for understanding the reproducibility of the analysis and thus the feasibility of centralization:~* hot spot on DNa (ddPCR/Sanger)~* fusion genes on RNA (target resequencing)~* Known mutation analysis by liquid biopsy (cfDNA) for somatic mutations with a mutation frequency of less than 10%~* Tumor type-associated gene sequence analysis by Sanger sequencing and NGS
Study NCT06175091 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: alarm management left to the discretion of the nurse
Description: alarm management left to the discretion of the nurse in charge of the patient
Study NCT06175091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: restrictive alarm use strategy
Description: more restrictive protocol for the use of alarms
Study NCT05870020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire (DBS-QoLs)
Description: The DBS-QoLs questionnaire will be sent to the patients for answer:~The questonnaire will be sent at :~* the inclusion~* 15 days after the inclusion~* 1 year after the inclusion
Study NCT05311618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGM438
Description: NGM438 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
Study NCT05311618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA ®)
Description: Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle.
Study NCT05578326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: 240 mg/m2 intravenous, over 30 minutes at day 1 of each cycle
Study NCT05578326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: 3.2 mg/m2, over 60 minutes at day 1 of each cycle
Study NCT05786820 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pycnogenol
Description: daily consumption of a pycnogenol-containing capsule
Study NCT05786820 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily consumption of a placebo capsule
Study NCT06031181 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sublobar Resection
Description: Sublobar Resection includes segmentectomy and wedge resection
Study NCT05458869 — intervention group
Intervention type: PROCEDURE
Intervention: HPV Self-Collection
Description: Use HPV self-collection kit
Study NCT05458869 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Attend interview
Study NCT05458869 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete surveys
Study NCT05450224 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: VVC-delivered Massed Imaginal Exposure
Description: Consistent with Zoellner et al., (2017), six, 60-minute daily sessions of imaginal exposure will be conducted based on the PE manual (Foa et al., 2007). No in vivo exposure or homework will be included. Session 1 will include rationale for imaginal exposure and common reactions to trauma. Sessions 2-6 will focus on imaginal exposure (45 minutes) and processing (15 minutes), with later sessions focused on the most distressing aspect of the trauma memory. The final session will include relapse prevention. All sessions will be delivered within a 10-day window.
Study NCT06517069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEAS
Description: Bilateral Neiguan point (PC6), Zusanli point (ST36) and Sanyinjiao point (SP6) were selected. Use Huatuo electronic needle therapy device, Sulodine electric stimulation hand circle TEAS, Huatuo electronic needle therapy device parameter setting: Density wave, 2/10Hz, current intensity from weak to strong, until the patient can tolerate the maximum intensity (acid, numbness, distension, pain) is appropriate, after the Sulodine brand electrical stimulation bracelet is turned on, gradually increase the stimulation intensity, until the patient can tolerate the maximum intensity is appropriate, stimulation for 30min until anesthesia induction
Study NCT06517069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Oxycodone 0.1mg/kg was injected intravenously 5 minutes before anesthesia induction
Study NCT05446038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Family Guided Self-Help FBT
Description: Previous research has shown that Family-Based Treatment (FBT) is an effective treatment for Anorexia. We hope to learn whether an adaptation of Family-Based Treatment (FBT), called online Multi-Family Guided Self-Help FBT, is feasible and acceptable for families of young people with Anorexia. The 'Self-Help' aspect of the treatment consists of a series of educational videos for parents about how to help their child with Anorexia, which parents watch on an online platform. The 'Multifamily' and 'Guided' aspects of the treatment consists of weekly meetings by Zoom for a group of parents of young people with Anorexia, with a facilitator present to guide a group discussion around whether parents feel they understood the content of the videos and whether the content is helpful.
Study NCT05965869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diabetes program
Description: CHWs will contact participants weekly via phone or text, send bimonthly diabetes education videos, and provide optional monthly seminars.
Study NCT06426563 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation treatment of thyroid nodule
Description: Use Radiofrequency or Microwave ablation device to treat thyroid nodule
Study NCT06433154 — intervention group
Intervention type: PROCEDURE
Intervention: Arthroscopic surgery
Description: Arthroscopic treatment (lysis and lavage) of internal derangement of the temporomandibular joint.
Study NCT05274971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active dietary management and aerobic exercise training.
Description: Active dietary management and aerobic exercise training.
Study NCT05175430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: Paroxetine (per os) will be used as pharmacological tool to downregulate 5-HT1/2 receptors.
Study NCT05175430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lysergic Acid Diethylamide
Description: LSD (per os) will be used to see if 5-HT 1/2 receptors were downregulated by paroxetine.
Study NCT05175430 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lysergic Acid Diethylamide
Description: LSD (per os) will be used to see if 5-HT 1/2 receptors were downregulated by paroxetine.
Study NCT05175430 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (per os) for the Paroxetine condition will be used to compare the data from the study day with LSD between both arms.
Study NCT06454279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual Task Training
Description: Exercise which combines cognitive task with motor task e.g Backward counting during sit ups.~Calculation questions during stationary cycle for 10 mins. Sequentially perform movements on commands like normal standing (bipedal support with feet separated at shoulder width, Feet together (bipedal support with feet side by side), Semitandem stance, Tandem stance, one leg support on the dominant leg, one leg support on the nondominant leg by first laterally moving the trunk with shoulder abducted at least above 60 degree
Study NCT06454279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task Specific Training
Description: Wide based gait training.~Auditory forward digit span:~Remember as many as possible of the number/letter forward sequence, you were told~Auditory backward digit span:~Remember as many as possible of the number/letter back sequence, you were told~Visual forward digit span:~Remember as many as possible of the number forward sequence shown to you by means of cardboard~Visual backward digit span:~Remember as many as possible
Study NCT03541889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLT imaging and TK1 blood measurements
Description: F18 labeled thymidine PET/CT scans will be performed. Serum measurements of TK1 will be obtained.
Study NCT05724953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affective Awareness
Description: Intervention involving psychoeducation and daily emotion awareness practices
Study NCT06251375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine is an α2-adrenergic agonist sedative commonly used in invasive mechanical ventilation that promotes patient wakefulness, has no effect on respiratory drive, has important analgesic properties, and when compared to γ-aminobutyric acid receptor agonists like benzodiazepines, reduces delirium.
Study NCT06251375 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline placebo will be given as continuous infusion.
Study NCT04829682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT for Life
Description: ACT for Life is a brief recovery oriented individual inpatient Acceptance and Commitment Therapy treatment protocol consisting of four modules typically administered in three to six inpatient sessions and one to four outpatient sessions in the 30 days following discharge from inpatient care. The immediate goals of ACT for Life are to increase the participant's psychological flexibility and readiness to cope effectively with future suicidal crises.
Study NCT04829682 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present Centered Therapy
Description: PCT is an evidence-based treatment for PTSD but its principles can be applied to psychotherapy for a wide range of difficulties. The standard PCT manual was originally adapted for suicide prevention by Craig Bryan and his colleagues. Our study team made additional minor revisions to prepare the manual for use as an active control condition in the current efficacy trial. PCT includes two initial sessions focused on discussion of current symptoms, psychoeducation, and the rationale for PCT. Current life problems become the focus of the remaining sessions. PCT is expected to consist of three to six, 60-90-minute inpatient sessions and one to four outpatient sessions in the 30 days following discharge. Discontinuation will occur when the participant attends an individual outpatient mental health appointment or 30 days after discharge, whichever occurs first. PCT participants will receive caring communications from their therapist for 12-months following inpatient discharge.
Study NCT04763252 — intervention group
Intervention type: OTHER
Intervention: Spectrum Therapeutics cannabis products
Description: For the purposes of this study, subjects enrolled will have been authorized Spectrum Therapeutics (ST) products that are commercially available in Canada. The full repertoire of Spectrum Therapeutics products are outlined on the website https://www.spectrumtherapeutics.com/canada/en/patients/products. It encompasses six colors (order from Red to Yellow follows the descending THC:CBD ratio), and five types of formulations: soft gels, spray, oil, flowers and vapes). Refer to webpage for the most up to date products available per country https://www.spectrumtherapeutics.com/canada/en/patients/products.
Study NCT06653803 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rhomboid Intercostal Block (RIB)
Description: Intraoperative Ipsilateral Ultrasound-guided RIB
Study NCT06653803 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrolaminar Block (RLB)
Description: Intraoperative Ipsilateral Ultrasound-guided RLB
Study NCT05117567 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Personal protection package
Description: A personal protection package that includes Long-lasting insecticidal hammock net (LLIHN), insect repellent (Icaridin), and MMP-tailored behavioural change communication (BCC) package
Study NCT05073484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT6021
Description: Ⅳ infusions
Study NCT05073484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1308
Description: Ⅳ infusions
Study NCT02077036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinetic Oscillation Stimulation Device
Study NCT02077036 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Kinetic Oscillation Stimulation Device in placebo mode
Study NCT06099808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audit and Feedback Emails
Description: Monthly email containing information including their total medication titration encounters over a 3 month period, as well as the site and VISN level for comparison. This will include rates of GDMT utilization and percentage of patients on >50% of the target dose of GDMT stratified by site, VISN and national. This data will be obtained from VHA national HF dashboard.
Study NCT06099808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Specific Targets
Description: Monthly emails include a list of 5-7 HF patients who are potentially eligible for pharmacist HF medication titration. This data will be obtained from VHA national HF dashboard.
Study NCT06099808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Resources
Description: Monthly educational webinars on pharmacist HF management and access to material and protocols on HF medication management.
Study NCT06099808 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Resources
Description: Monthly educational webinars on pharmacist HF management and access to material and protocols on HF medication management.
Study NCT06655363 — intervention group
Intervention type: OTHER
Intervention: Anatomical description
Description: Anatomical description of cervical ligament, calcaneo fibular ligament, interosseus talo-calcaneal ligament, talo-fibular ligament.
Study NCT06655363 — intervention group
Intervention type: OTHER
Intervention: Radiological (MRI) description
Description: Radiological (MRI) description of cervical ligament, calcaneo fibular ligament, interosseus talo-calcaneal ligament, talo-fibular ligament.
Study NCT06237439 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Move with HaRT
Description: Move with HaRT is a group-based, manualized mind-body intervention.
Study NCT05653284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK130
Description: IV infusion, specified dose on specified days.
Study NCT05010616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed orthodontic appliances
Description: Visual presentation of patient's predicted teeth alignment at the end of orthodontic treatment:~Presenting predicted teeth alignment after orthodontic treatment to patients before treatment starts, by using photos and videos of dental digital set-up.~Predicted teeth alignment can be described as: well-leveled and aligned patient's dental arches, well engaged posterior teeth and normal frontal teeth relationships.
Study NCT05679232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrogel coating
Description: hydrogel coating applied to implant's surfaces during cementless hip revision arthroplasty
Study NCT05679232 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: standard cementless hip revision arthroplasty
Study NCT05252117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine Hydrochloride 40 MG/ML
Description: Analysis of uterovaginal plexus block with articain for intrauterine device placement
Study NCT06053281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Daily Cholecalciferol 1000 IU in 24 weeks
Study NCT06053281 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06660862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: How darolutamide and hormone therapy affects the step count of older men who have prostate cancer
Study NCT06660862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physician choice Androgen Deprivation (Hormone) Therapy
Description: How step count/physical activity affects certain quality of life changes these men experience such as differences in pain, mood, function, memory and fatigue
Study NCT06662396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6552
Description: Oral Gelatin Coated Capsule
Study NCT06662396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: Oral Extended-Release Capsule
Study NCT06662253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Xa Guided Dosing of Low Molecular Weight Heparin
Description: Participants will receive Enoxaparin 0.5 mg/kg twice daily (rounded up or down to the nearest 10 mg) the initial starting dose. Dose adjustments will be made based on trough levels drawn between the 3rd and 4th dose. The target anti-Xa level range is between 0.1 and 0.2 IU/mL. If the patient is below the target range, then the next Enoxaparin dose will be increased by 10 mg per dose with a new trough anti-Xa level 24 hours after dose modification. If the patient is above the target range, then the next Enoxaparin dose will be decreased by 10 mg per dose with a new trough anti-Xa level 24 hours after dose modification. This dose will be maintained until hospital discharge.
Study NCT06662253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Dosing
Description: Participants will receive Enoxaparin dosed at the discretion of the most responsible physician (MRP). In cases of severe renal insufficiency (CrCl \&lt; 30mL/min\^:), the LMWH may dose reduced or changed to Heparin at the discretion of the MRP.
Study NCT06658587 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: No interventions
Description: No interventions
Study NCT06658223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise with virtual reality
Description: The virtual reality program consisted of twelve sessions (2 per week for six weeks) of 10 min warm-up plus 15 minutes of exercise with the FitXR game (developed by FITAR LIMITED) on the Oculus Quest 2™ device. The warm-up consisted of moderate-intensity aerobic exercise on a cycle ergometer. The BORG CR-10 perceived exertion scale was used to determine this intensity. Subsequently, they continued with the FitXR game, starting with a 5-minute phase of muscular activation and global movements of their limbs. They performed eye-hand coordination exercises, hitting balls that came to the person at different speeds, and ended with muscle stretching and slow breathing. These exercises presented different difficulty levels and were adjusted to the person's condition. In the same way, as the game developed, it was possible to increase the level and thus increase its complexity.
Study NCT06661252 — intervention group
Intervention type: DEVICE
Intervention: ABEL microsampler device
Description: The ABEL microsampler device will be used to collect nasal fluid samples for biomarker analysis.